| Literature DB >> 34950961 |
Nitikorn Phoosuwan1,2, Pranee C Lundberg3.
Abstract
PURPOSE: Breast cancer is the most common type of cancer found in women in Sweden and worldwide. Treatment leads to increased survival of patients, but they are at risk to experience psychological distress, including anxiety and depressive symptoms, and decreased health-related quality of life (HRQoL). This study investigated the relationship between psychological distress and HRQoL and related factors among women with breast cancer in Sweden.Entities:
Keywords: Anxiety; Depressive symptoms; Health-related quality of life; Support; Women with breast cancer
Mesh:
Year: 2021 PMID: 34950961 PMCID: PMC8857009 DOI: 10.1007/s00520-021-06763-z
Source DB: PubMed Journal: Support Care Cancer ISSN: 0941-4355 Impact factor: 3.359
Fig. 1Directed acyclic graphs for possible risk factors associated with a psychological distress and b quality of life among cancer patients
Number and percentage of sociodemographic and treatment characteristics among participants (n = 481)
| Characteristics | ||
|---|---|---|
| Age (years)a | ||
| Mean = 62.7, SD = 12.35, Min = 31, Max = 93 | ||
| Civil statusa | ||
| Married/ Live together | 321 (67.1) | |
| Single/alone | 157 (32.9) | |
| Education levela | ||
| Secondary school/unidentified | 226 (47.4) | |
| High school or university | 251 (52.6) | |
| Religiona | ||
| Christian | 422 (90.4) | |
| Non-Christian | 45 (9.6) | |
| Cultural/Ethnic minoritya | ||
| No | 455 (96.8) | |
| Yes | 15 (3.2) | |
| Having an underlying diseasea | ||
| No | 277 (59.3) | |
| Yes | 190 (40.7) | |
| Duration from diagnosis (year)a | ||
| Mean = 2.92, SD = 3.97, Min = 1, Max = 44 | ||
| Chemotherapy treatmenta | ||
| Yes | 234 (49.6) | |
| No | 238 (50.4) | |
| Radiation therapy treatmenta | ||
| Yes | 227 (52.6) | |
| No | 252 (47.4) | |
| Hormone therapy treatmenta | ||
| Yes | 293 (62.7) | |
| No | 174 (37.3) | |
| Herceptin treatmenta | ||
| Yes | 82 (18.7) | |
| No | 357 (81.3) | |
| Breast reconstructiona | ||
| Yes | 93 (19.7) | |
| No | 380 (80.3) | |
| Total score of support from physiciansa | ||
| Mean = 6.36, SD = 2.78, Min = 0, Max = 9 | ||
| Total score of support from nursesa | ||
| Mean = 4.60, SD = 3.22, Min = 0, Max = 9 | ||
| Total score of support from interneta | ||
| Mean = 0.75, SD = 1.71, Min = 0, Max = 9 | ||
| Total score of support from husband/partnera | ||
| Mean = 0.79, SD = 1.65, Min = 0, Max = 9 | ||
| Total score of support from family and friendsa | ||
| Mean = 0.77, SD = 1.56, Min = 0, Max = 9 | ||
| Total score of support from patient institutiona | ||
| Mean = 0.79, SD = 1.65, Min = 0, Max = 9 | ||
| HADS-Aa | ||
| Mean = 7.07, SD = 3.38, Min = 2, Max = 19 | ||
| HADS-Da | ||
| Mean = 14.10, SD = 2.14, Min = 7, Max = 19 | ||
aObtained number < 481; Hospital Anxiety and Depression Scale – Anxiety sub-scale (HADS-A); Hospital Anxiety and Depression Scale – Depression sub-scale (HADS-D)
Correlation between the scores of the Hospital Anxiety and Depression Scale – Anxiety sub-scale (HADS-A) and Depression sub-scale (HADS-D) and all dimensions of the Breast Cancer-Specific Quality of Life Questionnaire
| Variables | BRBI | BRSEF | BRSEE | BRFU | BRST | BRBS | BRAS | BRHL |
|---|---|---|---|---|---|---|---|---|
| HADS-A | 0.490* | 0.067 | 0.130 | 0.619* | 0.428* | 0.330* | 0.276* | 0.171* |
| HADS-D | 0.325* | 0.159* | 0.280* | 0.316* | 0.269* | 0.256* | 0.177* | 0.104* |
*Correlations were significant at 0.05 level
Body image (BRBI); sexual functioning (BRSEF); sexual enjoyment (BRSEE); future perspective (BRFU); systemic therapy side effects (BRST); breast symptoms (BRBS); arm symptoms (BRAS); and upset by hair loss (BRHL)
Multivariate linear regression analysis results of the scores of the HADS-A, HADS-D, and HRQoL
| Variables | Unstandardized Coefficients | Standardized Coefficients | ||||
|---|---|---|---|---|---|---|
| B | Standard error | 95% CI | Beta (Descending) | t | p | |
| HADS-Aa | ||||||
| Constant | 9.447 | 1.008 | 7.466, 11.428 | 9.374 | < .001* | |
| Age | − 0.065 | .014 | − .092, − .038 | − 0.230 | − 4.692 | < .001* |
| Having an underlying disease | 1.526 | .332 | .874, 2.178 | 0.219 | 4.599 | < .001* |
| Support from physicians | − 0.175 | .059 | − .291, − .059 | − 0.142 | − 2.965 | .003* |
| HADS-D | ||||||
| Constant | 14.443 | 0.143 | 14.162, 14.723 | 101.289 | < .001* | |
| Breast reconstruction | 0.626 | 0.252 | .130, 1.121 | 0.116 | 2.482 | .013* |
| Having an underlying disease | 0.501 | 0.115 | .099, .903 | 0.115 | 2.451 | .015* |
| BRBIa | ||||||
| Constant | 59.467 | 6.742 | 46.211, 72.722 | 8.820 | < .001* | |
| Chemotherapy | 8.027 | 2.301 | 3.503, 12.552 | 0.180 | 3.488 | .001* |
| Having an underlying disease | 7.761 | 2.278 | 3.283, 12.239 | 0.169 | 3.407 | .001* |
| Age | − 0.303 | .099 | − .498, − .108 | − 0.166 | − 3.059 | .002* |
| Breast reconstruction | 5.589 | 2.758 | .166, 11.011 | 0.102 | 2.026 | .043* |
| BRSEFa | ||||||
| Constant | 57.389 | 4.227 | 49.079, 65.699 | 5.987 | < .001* | |
| Age | 0.403 | .067 | .271, .536 | 0.281 | 5.987 | < .001* |
| Having an underlying disease | 5.530 | 1.643 | 2.299, 8.760 | 0.156 | 3.365 | .001* |
| Support from husband/partner | − 1.532 | .490 | − 2.494, − .569 | − 0.143 | − 3.129 | .002* |
| Belonging to a culture/ethnic minority | 13.531 | 4.694 | 4.303, 22.759 | 0.131 | 2.882 | .004* |
| BRSEEa | ||||||
| Constant/ | 25.446 | 8.902 | 7.885, 43.006 | 2.859 | .005* | |
| Age | .535 | 0.161 | .217, .853 | 0.247 | 3.316 | .001* |
| Education | 9.005 | 3.521 | 2.059, 15.951 | 0.191 | 2.558 | .011* |
| Support from husband/partner | − 1.703 | .789 | − 3.259, − .147 | − 0.145 | − 2.159 | .032* |
| BRFUa | ||||||
| Constant | 77.786 | 7.304 | 63.428, 92.144 | 10.649 | < .001* | |
| Age | − 0.548 | 0.097 | − 0.739, − 0.357 | − 0.272 | − 5.639 | < .001* |
| Having an underlying disease | 11.497 | 2.251 | 7.072, 15.922 | 0.230 | 5.107 | < .001* |
| Support from physicians | − 1.503 | .402 | − 2.293, − .713 | − 0.171 | − 3.741 | < .001* |
| Chemotherapy | 6.229 | 2.291 | 1.726, 10.732 | 0.127 | 2.719 | .007* |
| BRSTa | ||||||
| Constant | 28.431 | 1.578 | 25.328, 31.533 | 18.012 | < .001* | |
| Having an underlying disease | 8.391 | 1.180 | 6.071, 10.711 | 0.316 | 7.110 | < .001* |
| Chemotherapy | 5.118 | 1.174 | 2.811, 7.424 | 0.197 | 4.361 | < .001* |
| Support from family and friends | − 1.111 | .366 | − 1.830, − .393 | − 0.135 | − 3.040 | .003* |
| Support from physicians | − .631 | .212 | − 1.048, − .215 | − 0.135 | − 2.979 | .003* |
| BRBSa | ||||||
| Constant | 43.823 | 3.785 | 36.383, 51.262 | 11.579 | < .001* | |
| Radiotherapy | 7.040 | 1.255 | 4.572, 9.507 | 0.252 | 5.607 | < .001* |
| Belonging to a culture/ethnic minority | 16.237 | 3.718 | 8.928, 23.545 | 0.195 | 4.367 | < .001* |
| Age | − 0.226 | 0.054 | − 0.332, − 0.119 | − 0.196 | − 4.159 | < .001* |
| Having an underlying disease | 4.680 | 1.304 | 2.118, 7.242 | 0.164 | 3.590 | .018* |
| Support from nurses | − .477 | .200 | − .870, − .084 | − 0.110 | − 2.384 | .018* |
| BRASa | ||||||
| Constant | 28.234 | 1.265 | 25.746, 30.721 | 22.311 | < .001* | |
| Radiotherapy | 8.455 | 1.661 | 5.190, 11.721 | 0.265 | 5.090 | < .001* |
| Having an underlying disease | 8.462 | 1.457 | 5.597, 11.326 | 0.260 | 5.808 | < .001* |
| Chemotherapy | 3.991 | 1.655 | 0.738, 7.244 | 0.125 | 2.411 | .016* |
| BRHL | ||||||
| Constant | 32.794 | 1.879 | 29,100, 36.487 | 17.449 | < .001* | |
| Support from physicians | − .706 | .271 | − 1.238, − .174 | − 0.123 | − 2.608 | .009* |
| Belonging to a culture/ethnic minority | 10.450 | 4.430 | 1.744, 19.157 | 0.111 | 2.359 | .019* |
*A level of significance of 0.05
aChemotherapy and support from nurses were significant only in univariate analyses for HADS-A; radiotherapy, Herceptin, support from physicians, and from nurses were significant only in univariate analyses for quality of life – body image. Breast reconstruction, civil status, education, and support from physicians were significant only in univariate analyses for BRSEF. Chemotherapy and support from internet were significant only in univariate analyses for BRSEE. Civil status and support from nurses were significant only in univariate analyses for BRFU. Age was significant only in univariate analysis for BRST. Chemotherapy, civil status, and support from physicians were significant only in univariate analyses for BRBS. Age and support from physicians were significant only in univariate analyses for BRAS
HADS-A, F = 17.551, p < .001, Adjusted R = 0.107
HADS-D, F = 5.585, p = .004, Adjusted R = 0.020
BRBI, F = 11.067, p < .001, Adjusted R = 0.093
BRSEF, F = 21.160, p < .001, Adjusted R = 0.164
BRSEE, F = 11.775, p < .001, Adjusted R = 0.146
BRFU, F = 24.916, p < .001, Adjusted R = 0.184
BRST, F = 23.228, p < .001, Adjusted R = 0.173
BRBS, F = 19.798, p < .001, Adjusted R = 0.185
BRAS, F = 27.954, p < .001, Adjusted R = 0.160
BRHL, F = 6.377, p = .002, Adjusted R = 0.024
Hospital, Anxiety, and Depression Scale – Anxiety subscale (HADS-A); Hospital, Anxiety, and Depression Scale – Depression subscale (HADS-D); Health-Related Quality of Life (HRQoL); Quality of life – body image (BRBI); Quality of life – sexual functioning (BRSEF); Quality of life – sexual enjoyment (BRSEE); Quality of life – future perspective (BRFU); Quality of life – systemic therapy side effects (BRST); Quality of life – breast symptoms (BRBS); Quality of life – arm symptoms (BRAS); and Quality of life – upset by hair loss (BRHL)